Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Bone Diseases 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × BHQ880 × Clear all
NCT01302886 2020-12-17

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Novartis

Phase 2 Completed
41 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT01337752 2020-12-17

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Novartis

Phase 2 Completed
9 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT00741377 2013-02-18

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Novartis

Phase 1 Completed
28 enrolled
Plasma cell

Bone Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡